🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C45

Find Recruiting Clinical Trials for Mesothelioma

Search pleural and peritoneal mesothelioma trials — immunotherapy, chemotherapy, CAR-T, and novel targeted approaches.

🔍 Search Mesothelioma Trials →

About Mesothelioma

Malignant mesothelioma is a rare, aggressive cancer arising from mesothelial cells lining body cavities, most commonly the pleura (pleural mesothelioma) and peritoneum (peritoneal mesothelioma). It is strongly associated with asbestos exposure, with a latency period of 20–50 years. Prognosis is poor, with median survival of 12–21 months for pleural disease. The combination of nivolumab + ipilimumab (dual checkpoint inhibition) is now standard first-line therapy for unresectable pleural mesothelioma, improving upon historical platinum-pemetrexed chemotherapy.

What Types of Mesothelioma Clinical Trials Exist?

Mesothelioma trials are active across all lines of therapy. First-line trials test new checkpoint inhibitor combinations, novel IO agents, and chemotherapy optimization. Second-line and beyond trials test BAP1-targeted approaches, CAR-T cell therapies targeting mesothelin, ADCs (amatuximab), and VEGF pathway inhibitors. BAP1 tumor suppressor mutation status and histology (epithelioid vs. sarcomatoid vs. biphasic) are key prognostic and eligibility variables. Peritoneal mesothelioma has a distinct trial landscape including heated intraperitoneal chemotherapy (HIPEC) optimization trials.

Find Recruiting Mesothelioma Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Mesothelioma Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for mesothelioma?▾
Recruiting mesothelioma trials include checkpoint inhibitor combination studies (nivolumab + ipilimumab extension, novel PD-1/CTLA-4 combinations), mesothelin-targeting CAR-T cell therapies, ADCs (amatuximab, SS1P immunotoxin), VEGF inhibitors, and first-line chemotherapy intensification. Peritoneal mesothelioma has dedicated cytoreductive surgery + HIPEC trials.
Does asbestos exposure history affect mesothelioma trial eligibility?▾
Documented asbestos exposure history confirms the occupational/environmental context but is not typically a required eligibility criterion for mesothelioma trials — the confirmed histological diagnosis is what matters. However, it is important to document exposure history (occupation, duration, products involved) as it supports diagnosis and may be relevant to legal and insurance proceedings.
How does mesothelioma histology affect trial eligibility?▾
Histological subtype is a critical eligibility and prognostic variable. Epithelioid mesothelioma (60–70% of cases) has the best prognosis and broadest trial access. Sarcomatoid mesothelioma (10–15%) is more aggressive and may be excluded from some immunotherapy trials or specifically targeted by others. Biphasic mesothelioma (mixed) has intermediate prognosis.

Related Conditions

Lung CancerPancreatic CancerBladder Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.